Colorectal Cancer Alliance Announces 2022 Research Funding Opportunities
The National Nonprofit Seeks Proposals for Early Career Investigator and Pilot Awards with High Potential to Improve Colorectal Cancer Diagnosis, Treatment, and Survivorship
The national nonprofit Colorectal Cancer Alliance (Alliance) today announced a Request for Proposals (RFP) for innovative translational research. The Alliance plans to award 7 two-year grants totaling $850,000.
In this cycle, proposals will be accepted for Early Career Investigator Awards and Pilot Awards to support the training of committed CRC researchers and foster innovation. Of particular interest are proposals that address these areas of critical interest:
- Understanding the causes and improving interventions in young-onset CRC
- The prognostic and therapeutic value of the microbiome
- Development of combination therapies
- Understanding the causes and interventions for racial and ethnic disparities in CRC
Early Career Investigator applicants must submit an eligibility checklist by June 9. Full proposals for both mechanisms are due July 25.
"The Alliance believes in our path to ending colorectal cancer in our lifetime and is committed to investing in innovation," said Andrea Goodman, Senior Vice President of Patient Support and Research Strategy. "We are proud to fund translational research across the scientific continuum and according to our Research Investment Strategy to thwart this disease that is too often neglected and stigmatized."
The Alliance has already invested nearly $5 million in colorectal cancer research, including nearly $3 million as early-stage grants to innovative researchers. Highlighting the return on its investments, two grantees with early-stage funding from the Alliance have gone on to receive more than $6.5 million in federal research funding to expand their projects.
Colorectal cancer remains the second deadliest cancer in the U.S. While novel treatments, advancements in screening, and a focus on equity are improving survivorship, there is still a tremendous unmet need. Federal funding for colorectal cancer research still lags behind funding for other diseases, with no real change in government funding between 2006 and 2018. The Alliance has committed to investing $30 million over the next five years in innovative research.
About the Colorectal Cancer Alliance
The Colorectal Cancer Alliance is a national nonprofit committed to ending colorectal cancer. Working with our nation of passionate allies, we diligently support the needs of patients and families, caregivers, and survivors; eagerly raise awareness of preventative screening; and continually strive to fund critical research. As allies in the struggle, we are fiercely determined to end colorectal cancer within our lifetime. For more information, please visit colorectalcancer.org.
Top resources
FDA Clears Way for Colorectal Cancer Clinical Trial Led by Dr. Christopher Lieu
The U.S. Food and Drug Administration has given researchers at the University of Colorado Anschutz Medical Campus permission to begin a clinical trial of CAR T-cell therapy for people with advanced colorectal cancer who have already tried the standard treatments without lasting success.
Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for CRC: KLEOS
A first-of-its-kind trial platform in the colorectal cancer space, Project Cure CRC’s KLEOS is being driven by the Colorectal Cancer Alliance, the leading nonprofit dedicated to ending the disease, in collaboration with GCAR, a pioneer in the design and implementation of innovative clinical trials.
Alliance Presents Poster Sessions & Speaks at Symposium During AACR Annual Meeting
The Colorectal Cancer Alliance will present three poster sessions and deliver an oral presentation at the American Association for Cancer Research Annual Meeting 2026.